Background: Human rhinoviruses (HRVs) are one of the main causes of virusinduced asthma exacerbations. Infiltration of B lymphocytes into the subepithelial tissue of the lungs has been demonstrated during rhinovirus infection in allergic individuals. However, the mechanisms through which HRVs modulate the immune responses of monocytes and lymphocytes are not yet well described. Objective: To study the dynamics of virus uptake by monocytes and lymphocytes, and the ability of HRVs to induce the activation of in vitro-cultured human peripheral blood mononuclear cells. Methods: Flow cytometry was used for the enumeration and characterization of lymphocytes. Proliferation was estimated using 3 H-thymidine or CFSE labeling
Virus-induced exacerbations are the major cause of morbidity and mortality among asthma patients. Human rhinoviruses (HRVs) are the most common triggering factors of acute asthma exacerbations (1, 2) ; however, evidence demonstrating a causal relationship between HRV infection and asthma exacerbation is mostly limited to epidemiological studies and the immunological mechanisms are poorly understood. T helper (Th) 2 cells are considered the main initiating effector cell type in atopic asthma in general and asthma exacerbations in particular. However, exaggerated Th2 cell activities alone do not explain all aspects of asthma and exacerbations. In addition, they cannot explain susceptibility to viral infection, shared between asthma and chronic obstructive pulmonary disease (3) .
HRV was the first identified member of the Picornaviridae family. The picornaviruses are nonenveloped viruses with a single-stranded, positive-sense RNA genome. The family consists of twelve genera, including the Enterovirus genus, to which HRV belongs (4) . On nucleic acid identity, this genus can be subdivided further into ten species, from which three are HRV-A, HRV-B, and HRV-C. ICAM-1 (intercellular adhesion molecule 1, also known as CD54) is the virus entry receptor for the major group of rhinoviruses, such as HRV16 and HRV14 serotypes, and LDLR (low-density lipoprotein receptor) is the receptor for minor group rhinoviruses, such as HRV1B and HRV29 (5) . It has been recently found that HRV-C enters the cells using cadherin-related family member 3 (CDHR3) (6, 7) . ICAM-1 and LDLR are expressed on the surface of many different cell types, including those that are active in respiratory immune responses, such as monocytes and airway macrophages, dendritic cells, airway eosinophils, mast cells, B lymphocytes, and activated T lymphocytes (8, 9) . Less is known about the expression of CDHR3, but it is highly expressed in human lung tissue (10) and bronchial epithelium (7) .
Among terminally differentiated bronchial epithelial cells, HRV replication has been documented predominantly in ciliated epithelial cells (11) . The HRV-infected epithelial cells release a variety of inflammatory factors, which orchestrate proliferation, chemotaxis, and the activation of immune cells, resulting in an amplification of inflammation. It is generally believed that HRVs are not able to infect white blood cells. In contrast, it has been recently shown that HRVs are able to infect human macrophages (12) , T cells (13) (14) (15) , and Ramos cells (human B lymphocyte cell line) (16) . Even then, and similar to bronchial epithelial cells, only a small fraction of cells are positive for virus replication (12) . Innate activation of monocytes upon a viral infection (17) , and close contact of upper and lower airway epithelium cells with infiltrating inflammatory leukocytes, granulocytes, dendritic cells, and monocytes, suggests that these cells might influence the immune responses to HRV in vivo and be important to explain the processes during asthma exacerbations (18) .
In addition to the induction of asthma exacerbations, there is likely a causative link between HRV infections and the development of childhood asthma (19) , but yet fundamental questions persist about the mechanisms linking this common pathogen to the disease. As it is generally thought that asthma results from overzealous responses to innocuous antigens or poor regulation of the immune system, the details of how HRV infection interacts with the host immune system could be the key in uncovering the underlying mechanism of the development of asthma. Understanding disease pathophysiology is important for the development of effective and evidence-based treatments that are currently a major unmet need for both asthma exacerbations and asthma onset.
In the present study, we investigated the ability of HRVs to bind and activate lymphocytes using in vitro-cultured human peripheral blood mononuclear cells (PBMCs). We investigated the dynamics of infection in monocytes and lymphocytes and demonstrate for the first time that HRVs enter, form viral replication centers, and induce the strong proliferation of B cells.
Methods

Study subjects
Sixteen subjects (13 female and 3 male) adult volunteers participated in the study. All subjects were healthy in the moment of drawing blood. The status of possible infections was followed 3 days before and 3 days after drawing the venous blood and confirmed not to be other than healthy.
Generation of HRV stocks
HRV serotypes 14, 16, 1B, and 29 were propagated in Ohio HeLa cells using standard protocol (20) . Virus stocks were titrated by infecting HeLa monolayers with serially diluted HRV and assessing cytopathic effect to estimate their 50% tissue culture infective dose (TCID50)/ml by Kremser method. The identities of all HRVs were confirmed by neutralization using serotype-specific antibodies (ATCC). TCID50/ml was expressed as multiplicity of infection (MOI) based on TCID50; 0.1 ml of a TCID50 virus of 1e7 per ml on 1e6 cells would be an MOI of 1.
Ultraviolet inactivation of virus and 'Mock' solution
UV-inactivated virus was prepared by irradiating the virus suspensions in a 24-well tissue culture dish on ice for 10 min with a 75 W UV source (254 nm) at a distance of 5 cm. Treatment resulted in the complete loss of infectious titer as estimated by titration assay. To produce 'mock' solution, Ohio HeLa cells were cultured as for virus production without viruses to the culture.
Isolation and culturing of PBMCs
PBMCs were obtained from heparinized whole blood by Biocoll (Biochrom KG, Berlin, Germany) density gradient centrifugation. The cells were washed three times with PBS (0.02% EDTA added) and suspended in RPMI 1640 medium supplemented with L-glutamine (2 mmol/l), MEM vitamin, penicillin (100 U/ml), streptomycin (100 lg/ml), kanamycin, nonessential amino acids, sodium pyruvate (Life Technologies, Carlsbad, CA, USA), and 10% heat-inactivated fetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA). Further, we call the RPMI 1640 medium together with supplements as cRPMI (complete RPMI).
Culturing of PBMC with virus
PBMCs were exposed to HRV at MOI = 1.0 or 10 or other when indicated. As controls, UV-treated HRVs or no virus ('mock') was used.
Proliferation assay with 3 H-thymidine
After 5 days of stimulation with unlabeled active or UV-inactivated or without viruses (mock) in triplicate, PBMCs were pulsed for 8 h with 3 H-thymidine, harvested with a Tomtec plate washer, and counted on a Betaplate counter. The results were expressed as a stimulation index (SI).
CFSE labeling
PBMCs were washed in PBS twice and suspended in 10 ml PBS containing 5% FBS. CSFE (from 10 mM stock and at the final concentration of 5 lM) was added to the tube and immediately shaked vigorously. Labeling of PBMCs was done promptly 5 min at room temperature in the dark. The cells were washed three times in PBS supplemented with 5% FCS. Thereafter, cRPMI media were added and the cells were transferred to cell culture incubator (at 37°C under 5% CO 2 ) for further experiments.
Flow cytometry and cell sorting
For the expression of surface markers, the cells were stained with the following antibodies: CD3-FITC, CD16-FITC, CD19-ECD, CD19-PC5, CD4-PE/Cy7, CD14-APC/Cy7, CD19-Brilliant Violet 510, CD19-APC/Cy7. Matching isotype controls were used as negative controls. Samples were measured with a FACSAria II instrument (Becton Dickinson, Franklin Lakes, NJ, USA) or Gallios flow cytometer and analyzed using Kaluza software (Beckman Coulter, Brea, CA, USA). Dead cells were excluded based on staining with the eFluor 450 dye. Before imaging flow cytometry, CD14+ cells were sorted out from the rest of the cells according to the CD14-APC/Cy7 signal. To obtain purified CD14+ cells, we excluded from this cell population eFluor 450-positive cells as dead cell population.
Detection of infectious virions
PBMCs were infected with unlabeled-HRV16 at MOI 10 and incubated for 24 h at 37°C in tissue culture incubator using regular cell culture conditions. Then, the PBMCs were washed three times with prewarmed PBS and added to HeLa cells at a number of 800 000 cells per well in a 48-well plate (500 ll volume). Uninfected HeLa cells were seeded in these wells 24 h before and were growing in log phase when PBMCs were added. In the ICAM-1-blocking condition, anti-ICAM1-Ab was added to HeLa cells at the concentration of 1 lg/ml 2 h before PBMCs were added. Three days after the addition of PBMCs, HeLa cells were washed thoroughly to remove nonadherent PBMCs and RNA was isolated from HeLa cells using the RNeasy Micro Plus kit (Qiagen, Hilden, Germany). The expression of negative and positive strands of viral RNA was analyzed by RT-qPCR.
Labeling the virus with DyLight650
Labeling of viruses with DyLight650 was performed according to the manufacturer's-Thermo Scientific, Waltham, MA, USA-protocol. Shortly, media component in the virus (both active and UV inactivated) solution was replaced with PBS dialyzing it 2 times for 4 h with cold PBS (at pH 7.0 and 4°C). For dialysis, membrane MWCO of 6-8 kDa Spectra/Por Ò Dry Standard RC Dialysis Tubing (Spectrum Labs, Houston, TX, USA) was used. To the 15 ml samples was added 1 mg DyLight650 NHS Ester, mixed, and stained at RT for 1 h protected from light. Labeled and starting nonlabeled virus solutions were titrated by endpoint titration assay in parallel and stored at À80°C. Labeling caused the drop in virus infectivity 5 times when compared with the starting nonlabeled virus.
Imaging flow cytometry
The cells were labeled and promptly measured by cell imaging flow cytometer 'ImageStream'. To avoid overlapping of the APC/Cy7 signal with the side scatter signal on the 'ImageStream', the monocytes were sorted out with the cell sorter FACSAria before taking images on the 'ImageStream'. Signal strength was compensated between different channels according to the manufacturer's protocols. Flow speed was stabilized before collecting 30 000 events and 409 magnification was used for taking images. Data were analyzed using 'Ideas' software (Amnis, Seattle, WA, USA).
QuantiGene ViewRNA in situ hybridization
ISH was performed according to the manufacturer's-Affymetrix, Santa Clara, CA, USA-protocol. Shortly, PBMCs were added on top of the polylysine-coated microscopic slides. HRV or controls were added to the wells. Before cell fixation, media were carefully replaced with PBS. Thereafter, the cells were fixed with 4% paraformaldehyde and washed with PBS and dehydrated with ethanol at increasing concentrations (50%, 70%, and 100%). Slides were submerged in 100% ethanol at À20°C for storage. Before further analysis, the cells were rehydrated using decreasing concentrations of ethanol (70% and 50%) and washed with PBS. ISH was performed using QuantiGene ViewRNA protocols designed to detect specifically 20-nucleotide-long sequences in HRV vRNA-15 sites are for amplifying the signal and 5 sites are for blocking the nonspecific binding sites. The cells on the slides were permeabilized with working detergent solution (Affymetrix) and hybridized for 3 h at 40°C with customdesigned QuantiGene ViewRNA probes against positivestrand HRV1B and human actin-beta. Unbound probes were flushed out with wash buffer (Affymetrix). The bound probes were amplified through PreAmp (Affymetrix) hybridization for 1 h at 40°C, followed by Amp (Affymetrix) hybridization for 1 h at 40°C. Labeled probes (Affymetrix) targeting the individual probe types were added for 1 h at 40°C. The slides were covered in 4 0 ,6-diamidino-2-phenylindole (DAPI)-containing mounting medium and examined using an LSM 510 confocal microscope (Zeiss, Oberkochen, Germany).
Immunofluorescence
Microscopic slides with PBMCs after ISH were further incubated for 30 min with anti-human CD20 (MS4A1 RabMAb Ò , rabbit anti-human, Epitomics 1632-1, Epitomics, Burlingame, CA, USA) or with anti-rabbit polyclonal antibody (IC control), incubated for 30 min at RT in dark with secondary antibody [Alexa Fluor
The slides were covered in DAPI-containing mounting medium and examined using 'Leica TCS SPE confocal microscope' (Leica Microsystems, Wetzlar, Germany).
Cytokine measurement
PBMCs were cultured in cRPMI with or without HRV ('mock'). After incubation for 5 days, the cells were pelleted, and the supernatants were frozen (À80°C). 
Statistical analysis
Unless otherwise indicated, data show mean AE confidential interval (CI) 95%. Statistical tests were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and ggplot2 (H. Wickham -author). Statistical significance was determined using the 2-tailed Student's t-test or one-way ANOVA with Bonferroni's multiple comparison test to pinpoint the difference between two groups in multiple selections. Statistical significance was retained for P-value <0.05. The number of donors indicated in the figure legends includes all donors analyzed in the relevant experiment.
Results
HRV1B induces the proliferation of PBMCs
While most of the studies in the HRV field have focused on the relationship between HRVs and airway epithelial cells, we were interested in PBMCs, investigating how HRVs and human mononuclear cells interact. First, we cultured PBMCs from healthy donors with different concentrations of HRV1B and determined that HRV1B is able to induce the proliferation of PBMCs at a concentration range MOI = 1.0/10 in vitro. At lower and higher viral concentration, the proliferation was not detectable or not significantly different from baseline-'mock'-condition (Fig. 1A) .
Next, we studied which cell type(s) proliferate in response to HRVs. To measure the cell proliferation, we added carboxyfluorescein succinimidyl ester (CFSE) to the cells on day 0 and cultured PBMCs with HRV1B, HRV14, HRV16, or HRV29 at MOI = 1.0 or MOI = 10 for 3 and 5 days, and then stained the CFSE-labeled cells with antibodies recognizing CD19, CD4, and CD8 and performed flow cytometry. On the 5th day after infection, 6-13% or 14-33% of CD19+ B cells were detected as proliferating when PBMCs were infected with HRV1B, HRV14, HRV16, or HRV29 at MOI = 1.0 or MOI = 10, respectively. The remarkable exception was HRV16: Using higher viral concentration, MOI = 10 caused less proliferation of B lymphocytes even when compared with 'mock'-induced background proliferation. Only a small fraction of CD4+ or CD8+ T cells proliferated with statistically nonsignificant difference when compared to the 'mock' (Fig. 1B) . The proliferation of B cells was noticeable on day 3, but the difference from 'mock' condition was statistically insignificant (Fig. 1C) .
To confirm that HRV-induced B lymphocyte proliferation is not caused by unspecific stimulation of immune responses caused by the presence of virus components in the medium, we inactivated virus with ultraviolet (UV) radiation. No significant proliferation of PBMCs was observed in UV-treated HRV1B in comparison with nontreated HRV1B and HRV16 at MOI 1 and MOI 10 ( Fig. 1D) . ICAM-1 blocking partially decreased the proliferation of PBMCs approximately 40% (14-80%) during the virus stimulation (Fig. 1E ). This suggests that HRV may directly bind to PBMCs and induce Bcell proliferation.
These data suggest that HRVs are able to induce B-cell proliferation at certain viral concentration and time point in vitro.
HRVs can attach or enter to monocytes, CD4+ and CD8+ T cells and B cells
Next, we studied the HRV ability to attach and enter to the lymphocytes as the first events needed for the infection. We labeled HRV1B and HRV16 with fluorescent dye DyLight650 and performed flow cytometry analysis at different time points between 30 min to 24 h to estimate whether different cell populations take up HRVs. As controls, we used either UV-inactivated HRV1B and HRV16 or 'mock' condition. Figure 2A ,B demonstrates that HRV16 and HRV1B attached and probably also entered into the monocytes already 30 min and to CD4+ T and B lymphocytes 8 h after the addition of the virus. Monocytes were almost 100% positive for both UV-treated and untreated HRV16 and HRV1B at 24-h point of time. This indicates that in monocytes, the virus was at least partially taken up via passive internalization and not an active infection. Remarkably, 3.3% (AE0.2%) of CD4+ T cells and 2.9% (AE0.4%) B cells at 8 h and 14.0% (AE1.5%) of CD4+ T cells, 5.9% (AE1.5%) of B cells, and 7.4% (AE2.3%) of CD8+ T cells at 24-h time point were detected to be positive for HRV1B and HRV16 when the higher virus concentration was used. No positive signal of DyLight650-labeled HRV was detected in B cells, CD4+ T cells, and CD8+ T cells at lower virus concentrations and at higher concentration of UV-inactivated virus ( Fig. 2A,B) .
To further characterize the interactions of HRVs with different PBMC subsets, we performed imaging flow cytometry. PBMCs were cultured with higher concentration (MOI = 10) of DyLight650-labeled HRV1B and analyzed at different time points chosen according to the flow cytometry analysis results. The monocytes were analyzed for 1 h, while the B cells and CD3+/CD4+ and CD3+/CD4À T cells 24 h after the infection. Consistent with the flow cytometry results, the monocytes were detected to be positive for HRV1B 1 h after the infection and CD4+ T cells and CD19+ B cells 24 h after infection ( Figs 2C and S1-3 ). CD3+/CD4À T cells, representing CD8+ cytotoxic T-cell subset, did not give a positive signal in imaging flow cytometry (data not shown). In CD4+ T cells, DyLight650-labeled HRV1B was seen on cell surface where it colocalized with anti-CD4 staining ( Figs 2C and S2) , while in monocytes and CD19+ B cells, DyLight650 staining pattern indicates that DyLight650-labeled HRV1B was located inside the cells (Figs 2C, S1 and S3).
HRV forms viral replication centers in B cells and infectious virions in PBMCs
Next, we used in situ hybridization (ISH) for HRV1B to study whether we are capable of detecting viral RNA (vRNA) that would indicate that HRV could uncoat and infect PBMCs. PBMCs were cultured with infectious HRV1B and ISH was performed at 5th day ( Figs 3A and S4) , and as positive control, HeLa cells were cultured with infectious or UV-treated HRV1B and ISH was performed 1 day after infection (Fig. 3B) . As an additional positive control, we used ISH probes recognizing beta-actin mRNA that is strongly expressed during the activation or division of the cells. In PBMCs, vRNA signal was detected as an intracellular vesicle-like formation with the size around 200 -500 nm, which is 10 -25 times the size of the single viral particle, suggesting that we were able to detect viral replication centers, but not single vRNA with ISH ( Figs 3A and S4 ). Similar vRNA signal pattern was detected in 4 different donors. More intensive dotted intracellular signal was seen in HeLa cells (Fig. 4B) . Moreover, immunofluorescence analysis demonstrated that the vRNA signal often localized in the cells that stained positively with anti-CD20, a marker for nonterminally differentiated B cells. In conclusion, these data demonstrate that HRV1B can enter into B cells in vitro in cultured PBMCs. To demonstrate that HRV can replicate in PBMCs, we preinfected PBMCs with HRV16 and seeded them over uninfected HeLa cells after washing and then HRV RNA was analyzed in stringently washed HeLa cells after 72 h. Our data demonstrate that HRV can replicate efficiently in PBMCs and that newly produced virions may have the capacity to infect HeLa cells, as demonstrated by measuring viral RNA in the HELA cells. Figure 3C shows the expression of positive-and negative-strand viral RNAs in HeLa cells after all of the above procedures. UV-irradiated HRV was not able to infect PBMCs, and therefore, the virus was not able to replicate and reinfect HELA cells. Blocking of ICAM-1 on HeLa cells led to a reduced infection rate in HELA cells to about 57% (24-84%) of the virus load in average that was observed for the nonblocked infection condition. The same results were obtained in both positive-and negative-strand mRNA detections.
The cytokine profile of HRV-infected PBMCs
To explore whether and how different HRVs stimulate immune responses that possibly support the observed B-cell proliferation, we next determined the profile of chemokines/ cytokines produced by PBMCs. We infected cultured PBMCs using the same experimental settings as in Figs 1-3 , collected the supernatants on day 5 after HRV infection, and measured the panel of 27 cytokines. All used viral strains upregulated IL-6, IFN-a, IL-10, IFN-c, and RANTES. MIP1b, IL1beta, IL-6, and TNF-a were stimulated more strongly upon the shape of cells. CD14+ monocytes were sorted out 1 h after incubation with the virus by cell sorter and then analyzed for DyLight650-labeled HRV1B (red). T lymphocytes were analyzed for surface markers using anti-CD3 FITC (green) and anti-CD4 PE/Cy7 (purple) and for DyLight650-labeled HRV1B (red) 24 h after incubation with the virus. B lymphocytes were analyzed with anti-CD19 FITC (green) for DyLight650-labeled HRV1B (red) after 24-h incubation with the virus.
HRV16 infection (Fig. 4) . All viruses induced IFN-a production, but minor group rhinoviruses, HRV1B and HRV29, induced significantly stronger expression of IFN-a at MOI = 10. For major group viruses, HRV16 and HRV14, there was no significant concentration-dependent difference in the induction of IFN-a. IFN-c was significantly strongly expressed at all virus types compared to 'mock' with the exception HRV16 MOI = 10 and HRV29 MOI = 1, where there was no significant difference. Interestingly, HRV16 MOI = 10 concentration did not increase the IFN-c production, and at the same time, IL-10 production was found to be strongly upregulated. IL-27 was upregulated by major HRV types, HRV16 and HRV14, and was observed to be more strongly expressed at MOI = 1. These results show that HRVs induce immune responses in cultured PBMCs with moderate differences between the virus strains.
Discussion
The mechanisms of the development of immune responses to HRVs and the causal relationship between HRV infection and asthma exacerbation are not completely understood. In the current study, we demonstrate that monocytes, CD4+ T cells, CD19+ B cells, and CD8+ T cells are able to interact with HRVs in in vitro-cultured PBMCs. More importantly, we show that HRVs enter and can induce the proliferation of CD19+ B cells. In addition, we demonstrate that HRVs activate PBMCs and induce the production of inflammatory cytokines MIP-1b, IL-1b, IL-6, TNF-a, IFN-a, IL-10, RANTES, IFN-c, and IL-27. During the last several decades, strong evidence has accumulated supporting the idea that HRV infections enhance allergic inflammation in the airway leading often to an increased asthmatic symptom-asthma exacerbation (2, (21) (22) (23) . Most commonly, HRVs infect only URT epithelial cell lining, and for most of us, HRV infection causes only a relatively mild illness with upper respiratory tract symptoms as seen during the common cold (24) . Remarkably, more than 50% of bronchial epithelial biopsies collected from patients during virus-induced asthma exacerbation have found to be HRV positive (25) .
While the research has been focused mostly on viral infection in bronchial epithelia as the principal site of viral replication, the capacity of HRVs to directly infect immune cells and to modulate immune responses has been studied less. Still, Levandowski et al. (26) demonstrated that the total lymphocyte count of infected individuals was significantly reduced on day 3 after the challenge with a rhinovirus of the minor group. In addition, they showed that specifically T lymphocyte numbers were reduced, while B lymphocyte levels were constant. Decreased cell populations positively correlated with the disease severity. In addition, virus shedding was the highest in individuals with the greatest reduction in lymphocytes. The reduced number of lymphocytes in the circulation might be at least partly explained by a massive lymphocytic and eosinophilic infiltration into the infected tissues. This cell infiltration to bronchial mucosa might be responsible for changes in airway hyper-responsiveness and asthma exacerbations (27) . Viremia may occur during HRV respiratory tract infections, suggesting that rhinoviremia may be involved in asthma exacerbation pathogenesis (28) . In addition, Gern et al. (29) showed that the activation of T cells estimated by CD69 was detectable at HRV16 MOI of 0.03, with maximum CD69 expression occurring with a MOI of 1. UV irradiation did not significantly increase T-cell CD69 expression. The narrow range of viral concentration was similar to what was observed in our experiments with B cells. Bcell proliferation reached its highest values on days 3 to 5, while the HRV induces no statistically significant proliferation of B lymphocytes during first 48 h as it has been noticed already by Papadopoulos et al. (30) , but still they observed a suboptimal Th1 response in PBMCs from atopic asthmatic subjects and differential expression of costimulatory molecules. It was also dependent on the virus strain and concentration, which was optimum around MOI 1 and 10 showing the difference between the viral strains.
As a novel approach, we followed the dynamics of virus attachment and uptake by different PBMC populations using virus particles labeled with DyLight650. Uptake of the HRV by all leukocytes was observed 20 years ago using [ 35 
S]
HRV16, and from these experiments, it was known that HRV16 attaches to all types of leukocytes and has fourfold higher binding effect to monocytes (29) . We directly visualized the attachment by imaging flow cytometry and describe here first time the kinetics of it by conventional flow cytometry. DyLight650 dye contains N-hydroxysuccinimide (NHS) esters, which react with the amines on the virus capsid proteins, thereby labeling the viral capsid proteins with red fluorescent dye. One should understand that labeling is present only on the parent generation of viruses and it will be lost during viral replication. We observed that monocytes internalize HRV-and UV-inactivated viruses. This indicates that the uptake of HRV particles by monocytes is at least partially a passive event and not only via receptor-mediated infection. B and T lymphocytes had distinct attachment and/ or internalization pattern in the case of functional virus and no signal with UV-treated viruses was detected. There was a lag time around 8 h before HRV was detected in B and CD4+/CD8+ T cells. In the case of CD4 T cells, the DyLight650-labeled virus signal overlapped CD4 signal that points to the attachment of virus to CD4. Our results were concordant with the previously reported results about the attachment of HRV to different types of leukocytes (29), but give better understanding of the kinetics of the process which allows better to plan experiments similar to further study of HRV-leukocytes interactions.
In addition to DyLight650 labeling, we used ISH for viral RNA as the second visualization method. We were able to detect the accumulation of vRNA on the surface and inside of B cells. The size of the vRNA signal, which is found on B cells, indicates that these clusters are viral replication centers. Additionally, we demonstrate that HRV-infected PBMCs were able to transfer the infectious particles to other cells, as shown by measuring virus RNA expression in HELA cells after coculture with preinfected PBMCs. These findings indicate strongly that HRV is able to replicate inside the peripheral blood mononuclear cells. It might seem to contradict with the study conducted 20 years ago where it was shown that the viral titers decrease over time when PBMCs were exposed to HRV16 (MOI = 10, 72 h), suggesting that no type of cells in PBMCs develops effective infection (29) . Still, the authors found HRV RNA in the cytoplasm of monocytes as we did, but no viral RNA synthesis was detected. But other studies showed later that under certain conditions (especially timing and choice of 'right' viral concentration are important), HRV is still able to infect alveolar macrophages (12) , T cells (13), and Ramos cells (B-cell line) (16) . Definitely, the discussion stays open while the studies are conducted in vitro and the topic needs further studies to clarify whether the infection of lymphocytes (besides alveolar macrophages) is relevant in vivo. We observed that HRVs are able to induce B-cell proliferation. The rate of proliferation was time, virus type, and dose dependent. HRV-induced lymphocyte proliferation was slightly detectable at lower (MOI < 1.0) viral concentrations, heavily dampened at higher concentrations (MOI > 10), and clearly visible in the range of MOI = 1.0/10. HRV16 was exceptional as the proliferation dampening happened earlier at lower viral concentration (MOI = 10), suggesting that its virulence might be stronger. Similar to our results with HRVs, other picornaviruses, such as poliovirus and Coxsackie virus, efficiently induce the proliferation of B cells, which start to produce IgM independently from T helper cell (31) . It is known that T-cell-independent antibody response results from extensive B-cell receptor cross-linking by the highly organized, repetitive picornavirus virion structure and is postulated to be generally characteristic of antibody-controlled cytolytic viruses (31) .
It has been shown that major group rhinoviruses significantly inhibit T-cell proliferation (32, 33) . We did not observe the induction of neither CD4+ nor CD8+ T-cell proliferation in PBMCs with any of used virus strains even in the conditions where B lymphocytes proliferated. T-cell proliferation upon HRV was confirmed couple of years ago, but as authors pointed out, the viral concentration needed to be very low-1000 more diluted-and the T-cell proliferation was detected later on the day 5 -7 when compared with our experiments, and it explains why we did not detect the T-cell proliferation, but these two studies show how sensitive is the event of lymphocyte proliferation to the chosen condition. The mechanism how HRV inhibits antigen-specific CD4+ or CD8+ T-cell proliferation is known to be ICAM-1 dependent (32). Our results indicate that there might be a similar regulatory mechanism through the LDL receptor as minor group HRVs, HRV1B and HRV29, also did not induce T-cell proliferation.
A recent study demonstrated that B lymphocytes play an important role in the induction of asthma-like inflammation in mice (34) . It has also been suggested that B lymphocytes may become increasingly relevant as antigen-presenting cells when antigen load is low even without the help of CD4+ T lymphocytes (35) . It is possible that in allergic/asthmatic individuals, HRVs infect not only LRT epithelial cells but also underlining infiltrating immune cells in the inflamed epithelium, which ultimately may lead to a strong nonspecific induction of B-cell proliferation in bronchial tissue. This might lead to a rapid increase in the total serum IgE, as observed previously (36) , and therefore can provide a synergistic link between allergy, HRV infection, and exacerbation of asthma (20) .
In conclusion, this study provides first time evidence that HRVs can be taken up and induce the proliferation of B lymphocytes and suggests that the mechanism how HRV induces B lymphocyte proliferation and activation can be promising target for new therapeutic intervention strategies for asthma exacerbation. 
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Figure S1 were sorted out 1 h after incubation with the virus by cell sorter and then analyzed for DyLight650-labeled HRV1B (red) (A) and DyLight650-labeled and UV-treated HRV1B (B). Figure S2 Imaging of HRV uptake by CD4+ T cells. Brightfield (BF) image shows the shape of cells. CD4+ T lymphocytes were analyzed for surface markers using anti-CD3 FITC (green), anti-CD4 PE/Cy7 (purple) and for DyLight650-labeled HRV1B (red) 24 h after incubation with the virus. PBMCs were cultured with DyLight650-labeled HRV1B (A) and DyLight650-labeled and UV-treated HRV1B (B) and CD4+ T cells were sorted out 24 h after incubation with the virus by cell sorter. Figure S3 Imaging of HRV uptake by CD19+ B cells. Brightfield (BF) image shows the shape of cells. B lymphocytes were analyzed for surface markers using anti-CD19 FITC (green) and for DyLight650-labeled HRV1B (red) 24 h after incubation with the virus. PBMCs were cultured with DyLight650-labeled HRV1B (A) and DyLight650-labeled and UV-treated HRV1B (B) and B lymphocytes were sorted out 24 h after incubation with the virus by cell sorter. Figure S4 Donor 5 (D5) -HRV1B is inside the B cell. HRV1B vRNA is designated with green, human beta-actin mRNA with red, DAPI with blue, and anti-CD20 as the marker for B cells with purple color. PBMCs were cultured with HRV1B and subjected to ISH analysis on 5th day. Cells images are different slices to visualize the localization of HRV replication centers.
